Financial Performance - The company's operating revenue for Q3 2025 was ¥342,707,426.71, a decrease of 20.63% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2025 was ¥5,115,431.80, an increase of 109.11% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥105,723.49, up 100.17% from the previous year[5]. - Total operating revenue for the current period was ¥1,102,095,711.13, a decrease of 16.5% compared to ¥1,320,029,736.34 in the previous period[24]. - Total operating costs decreased to ¥1,065,770,911.06, down 17.9% from ¥1,298,282,175.55 in the previous period[24]. - Net profit for the current period was ¥10,207,252.28, a significant recovery from a net loss of ¥53,179,196.56 in the previous period[25]. - The total comprehensive income for the current period was ¥10,207,252.28, recovering from a loss of ¥53,179,196.56 in the previous period[25]. - Basic and diluted earnings per share were both ¥-0.0017, an improvement from ¥-0.1026 in the previous period[25]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥171,758,891.35, a significant increase of 707.47%[12]. - The company reported a net cash flow from operating activities of ¥171,758,891.35, compared to a negative cash flow of ¥28,274,515.34 in the previous period[26]. - The net cash flow from investing activities improved by 45.13%, amounting to -¥26,617,005.57, as the acquisition of long-term assets decreased[13]. - Net cash flow from investing activities was -$26.62 million, an improvement from -$48.50 million in the previous period[27]. - The net cash flow from financing activities was -¥227,607,418.10, a decrease of 128.75% primarily due to dividend payments[13]. - The net cash flow from financing activities was -$227.61 million, worsening from -$99.50 million year-over-year[27]. Assets and Liabilities - Total assets at the end of Q3 2025 were ¥2,430,758,449.35, down 7.34% from the end of the previous year[5]. - The total assets decreased to ¥2,430,758,449.35 from ¥2,623,334,426.70, a reduction of approximately 7.3%[21]. - Total current assets decreased to ¥1,843,699,090.36 from ¥1,998,640,598.09, a reduction of approximately 7.8%[19]. - Total liabilities decreased to ¥760,428,114.90 from ¥802,997,927.54, a decline of about 5.3%[21]. - The company’s total equity attributable to shareholders decreased by 4.85% to ¥1,577,756,499.98 compared to the end of the previous year[5]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,745[15]. - Shanghai Lanwei Investment Co., Ltd. holds 37.34% of shares, totaling 149,554,017 shares[15]. - The company has a total of 1,996,100 shares in the repurchase account, accounting for 0.50% of the total share capital[16]. - The number of restricted shares held by Sun Linjie is 4,805,680, all of which are executive lock-up shares[17]. - The company has no changes in the top 10 shareholders due to margin trading or securities lending[16]. Expenses and Costs - Research and development expenses were ¥38,357,166.74, down 14.6% from ¥44,916,908.61 in the previous period[24]. - The company achieved a gross profit margin of approximately 3.3% for the current period, compared to a negative margin in the previous period[24]. - The company recorded a significant decrease in credit impairment losses, which were ¥-13,501,833.70, compared to ¥-30,771,031.56 in the previous period[25]. - The company reported a significant decrease in financial expenses, down 55.71% to ¥2,193,528.37 due to reduced bank loans[11]. Audit Information - The company did not undergo an audit for the third quarter financial report[28].
兰卫医学(301060) - 2025 Q3 - 季度财报